Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PTLocation: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/ About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Media & Investor Contacts:Carl Mauchcmauch@vorb
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.MarketBeat
- Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of DirectorsGlobeNewswire
- Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Vor Bio Announces $150 Million Private PlacementGlobeNewswire
VOR
Earnings
- 11/13/25 - Miss
VOR
Sec Filings
- 1/12/26 - Form 8-K
- 1/2/26 - Form 8-K
- 12/23/25 - Form SCHEDULE
- VOR's page on the SEC website